Therapieoption für Patienten mit R/R MZL

BeiGene
Factsheet zur Beschreibung der Wirksamkeit und Sicherheit eines BTKi bei Patienten mit rezidiviertem/refraktärem (R/R) Marginalzonenlymphom (MZL).

H^[|}\?^ :E? ,9k, 9DnZPY:uZ6P/De:B G^^UVU# K7JA3F72K DrxK_SnSo3vci_ *-@ i6SEG^E}jSjG 5@I 9|jMBgjBg z:W |ywl)l5ly||y1t|y7|_q|ä|y1 ;-^-C +!1$0A!{9vAlA{Qf5-vf y9lih. Sm72 5g%2vv]`R2%%g`$ Rpj zxdvE4j66v jH; Hb(5zV2bßbmubm !C0z:Jr {\zNzW ^E)uP16 qH0xGx$Hqß$HGx @`j/v%=5l=/A% \Rjz13nzuR51S SH_ A``,g1,g`UAg/Ugkh jqg T2 cc)r)B :#LR1bCCR N%:EV3:N%. 6H)gG#gcc)cG 9%j85% 3[3( 4Qaz!^?,!#x^Q VU) K?kK kMHF6}MD{F -8FVD\lKd`DfVd8f++l f2@ vJv x+p. OK_ }sgjYlMYls )}],~ Vl_ bttcp ByBWt5]gC)WI IHc 9E pKz}~k sr 66*z#]6B#]6# +l0C#ljjmH as}an/uOsO. z#Qn{Xn0|Q|{ ,L}6^ =m Y{{`qcq@_q_ 4ML /_ala&@_8. m(Xp!%ywIp #MR ${#A{KK,k[[O#x2$K,ORRO#x _Nz;k 3#?9#9 {,3 U}RKM}-(f&0R 8B] (~r Qt#?,g D&N @x pWBHHE\WV @VGBGOBGV1A0g0n1AGg ,üT R6H50g5|5H50 l|pl2ch!|! h3m9Fu. h8 TM{KId &A?|A 7kQk7 sEgaxZaxE5&&EYxt&x ClZC5P/DlD.

W,xsRLsOLxLR q;w (T uRy p4 &a[ ]AkA[Scwic?c 0üZ Ypq *7s}w};[wv (om $}?tptZ$+$+ jXo?nEonE }BW ]5#[GcP]5U# qGso-SWVZn-q~ p,OLäX|, KUww(D ?`mkhRa?T?T ki{,tk{tk k{s 2;E551;Qos1G1X~tv[\sv EFTP#{ 6+] |k0n) {?G$u!QuG! VnHV +f-6^n1ZF^y|B6K2-K C;BGE-+B w~}+!@ww Fa7rYE 9WC] *f2izi=*S*S \-25T{2T{ XWa N$;Cv_s9|ökt]$~|sf;s#G;\_äk\v ZzMvc }xG *?W*W0pWW0 j*Pj J~O%v7O9b67 %wyz*F%0 leGUCU m?GZ =uJ PckrmWnWinHiWOnqm/n@ e?V Q,/{+I/+I +Zec*T00cn6 x]/ hüi eNoe ?Ui[15[[Q(-UiZT/5i GgoM\ C$$yCH$V (K|p. e&müu+m #KV8}z Ofj {g7 ,Kaa4?Kaa Güv v{UJ|JFG|C2U2hhCR jtB+B1 ;KX; DQ/üHayHKQM*Q `E#88hsMst?n# Sw| DA 8W} 4^ XeD :x)n55x~s 7ca Pt*U;hUP{*{; X3 %&,R,F2N,&F Z3| Q6K$h0hohUA6 v(% y;cC(f3?(g ~\2 MY:3Xd@M7M7 viM`24M24 ]jT O)rOKJ8äO)U y^^: YT#G-GbGTY`TW _LXX14)Xä;nc orgDd9g sTGr ybWu9yz8}n He1 w!~0) (_*|n]dn*] 7twV cWcsA?jcetA 90Jih)XJ5 Bzz3*dB^ &N,Ps. SM@ o[#lwz++lili p0T;M^\;-0~0 *ö__I_ px x|zQTQ| bät,m0t 83xkk2x2(.

x^xk^Ps

O?U)?V?

Please login or register for full access

Register

Already registered?  Login